Cytochrome p-450 polymorphisms and response to clopidogrel.

@article{Mega2009CytochromePP,
  title={Cytochrome p-450 polymorphisms and response to clopidogrel.},
  author={Jessica L Mega and Sandra L. Close and Stephen D. Wiviott and Lei-Bin Shen and Richard D. Hockett and John T. Brandt and Joseph R. Walker and Elliott Marshall Antman and William L. Macias and Eugene Braunwald and Marc S. Sabatine},
  journal={The New England journal of medicine},
  year={2009},
  volume={360 4},
  pages={
          354-62
        }
}
BACKGROUND Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function. METHODS We tested the association between functional genetic variants in CYP genes, plasma concentrations of active drug metabolite, and platelet inhibition in response to clopidogrel in 162 healthy subjects. We then examined the association between these genetic… 

Figures and Tables from this paper

Cytochrome P 450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic , Pharmacodynamic , and Clinical Outcomes
TLDR
Common functional CYP genetic variants do not affect active drug metabolite levels, inhibition of platelet aggregation, or clinical cardiovascular event rates in persons treated with prasugrel, and these pharmacogenetic findings are in contrast to observations with clopidogrel.
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
TLDR
Common functional CYP genetic variants do not affect active drug metabolite levels, inhibition of platelet aggregation, or clinical cardiovascular event rates in persons treated with prasugrel, and these pharmacogenetic findings are in contrast to observations with clopidogrel.
Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease
TLDR
Intermediate and poor metabolizing CYP2C19 polymorphism is associated with reduced clopidogrel antiplatelet activity in patients with cerebrovascular disease.
Cytochrome P450 2C19 genotyping for clopidogrel response - the state of play.
TLDR
While meta-analyses consistently observe an association of CYP2C19 genotype with clopidogrel responsiveness, an association with cardiovascular events is less clear, which may explain the lack of association identified in large cardiovascular event studies.
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?
TLDR
The role of pharmacogenetics and drug interactions in determining variability in response to clopidogrel is summarized.
Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease
TLDR
Findings indicated that only CYP2C19*2 and *3 alleles had an influence on clopidogrel resistance and there was no evidence of gene-gene interaction or LD between CYP 2C19 and PON1 polymorphisms on ADP-induced platelet aggregation.
Routine genotyping of patients on clopidogrel: Why the resistance?
Genetic and nongenetic factors influencing the response to clopidogrel
TLDR
A genetic test to identify potential responders to clopidogrel might be useful, but the use of such tests is currently limited because they focus mainly on CYP2C19 loss-of-function alleles, and there is no empirical evidence yet for genotype-guided clopIDogrel therapy.
...
...

References

SHOWING 1-10 OF 45 REFERENCES
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
TLDR
The CYP2C19*2 loss-of-function allele is associated with a marked decrease in platelet responsiveness to clopidogrel in young healthy male volunteers and may therefore be an important genetic contributor to clopsinogrel resistance in the clinical setting.
Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel
TLDR
The IVS10+12G>A polymorphism of the CYP3A4 gene modulates platelet activation in patients treated with clopidogrel and may therefore contribute to clopIDogrel response variability.
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
TLDR
Multivariable analysis showed that the CYP3A5 polymorphism was a predictor of atherothrombotic events in clopidogrel users, which may be associated with worse outcomes in patients with the non-expressor genotype who are given clopIDogrel after coronary angioplasty and implantation of bare-metal stents.
2 C 19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
TLDR
The CYP2C19*2 loss-of-function allele is associated with a marked decrease in platelet responsiveness to clopidogrel in young healthy male volunteers and may therefore be an important genetic contributor to clopsinogrel resistance in the clinical setting.
The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance
TLDR
It is clear that the CYP2C19 genotype affects the plasma levels of clopidogrel and modulates the antiplatelet effect of clopsinogrel.
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently
TLDR
CYP3A4 and CYP3A5 inhibition by ketoconazole affects formation of clopidogrel's but not prasugrel's active metabolite, which is associated with reduced IPA.
Influence of cytochrome P 450 polymorphisms on drug therapies : Pharmacogenetic , pharmacoepigenetic and clinical aspects
TLDR
It is concluded that the pharmacogenetic knowledge regarding CYP polymorphism now developed to a stage where it can be implemented in drug development and in clinical routine for specific drug treatments, thereby improving the drug response and reducing costs for drug treatment.
Cytochrome P 450 2 C 19 681 G > A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
TLDR
Between *2 carriers and wild-type homozygotes, the authors found significant differences in the proportion of patients with RPA 14%, both after loading and at pre-discharge, which incurred a 3.0-fold increase in the 1-year incidence of death and myocardial infarction.
...
...